Natural Gels for Treatment of Plaque Psoriasis

Safety and Efficacy of Natural Gel Combination and Hair Mask of Plant Origin in Patients With Psoriasis: A Randomized, Double-Blind, Placebo (Vehicle) Controlled

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02330237

Enrollment

Registered

2015-01-01

Start date

2015-01-31

Completion date

2017-09-30

Last updated

2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parapsoriasis

Brief summary

The aim of the study is to evaluate the safety and the therapeutic activity of the combination of Natural Gel combination and hair mask of plant origin in patients with mild to moderate plaque psoriasis.

Detailed description

This is a random, double blind placebo -vehicle- controlled study. Patients recruiting and inclusion into the study is well defined. Expert on site monitoring will assure execution of all assignments as detailed in the protocol (screening, consent form, double-blind group assignment) . Statistical analysis: * It is calculated that 52 patients will be needed for this study. * Type I error probability associated with this test is 0.05 . * Uncorrected chi square will be used to assess changes in the measured variables.

Interventions

DRUGnatural gels

whole fruits and vegetables

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Subjects with stable (for at least 6 months), mild to moderate (less than 10% of the skin surface area) plaque psoriasis. 2. Male and female ≥ 18 years old. 3. Subject is capable of giving a written informed consent.

Exclusion criteria

1. Subjects treated by topical or photo or systemic anti psoriatic therapy during 4 weeks prior to the study. 2. Subjects treated with Biological products for psoriasis for the last 3 months prior to starting the present study. 3. Subjects with any other type of psoriasis but vulgaris (plaque ). 4. Use of investigational agents \< 30 days prior to the study. 5. Low compliance. 6. Subjects who are mentally or physically unable to comply with all aspects of the study. 7. Pregnant women. 8. Known allergic reaction to fragrance or any ingredient of the test products. 9. Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis. 10. A medical condition that may put the patient at a general risk and therefore would prevent participation in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Modified Psoriasis Assessment severity index	up to 16 weeks

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026